ranolazine has been researched along with Pulmonary Arterial Remodeling in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alemanni, M; Altomare, C; Barile, L; Cornaghi, L; Gobbi, M; Latini, R; Lucchetti, J; Mostacciuolo, G; Rizzetto, R; Rocchetti, M; Ronchi, C; Russo, I; Sala, L; Staszewsky, LI; Zambelli, V; Zaza, A | 1 |
1 other study(ies) available for ranolazine and Pulmonary Arterial Remodeling
Article | Year |
---|---|
Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Topics: Acetanilides; Animals; Calcium Signaling; Collagen; Disease Models, Animal; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Membrane Potentials; Monocrotaline; Myocytes, Cardiac; Myosin Heavy Chains; Piperazines; Pulmonary Artery; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium; Sodium Channel Blockers; Sodium Channels; Time Factors; Vascular Remodeling; Vascular Resistance; Ventricular Function, Right; Ventricular Remodeling | 2014 |